Latest News on TARS

Financial News Based On Company


Advertisement
Advertisement

Form 4 Tarsus Pharmaceuticals Inc: Bobak R. Azamian (Director, President/CEO and Board Chair) For: 13 November

https://ng.investing.com/news/stock-market-news/form-4-tarsus-pharmaceuticalsinc-bobak-r-azamian-director-presidentceo-and-board-chair-for-13-november-93CH-2814409
This article reports on a Form 4 filing for Tarsus Pharmaceuticals Inc., indicating insider transaction activity by Bobak R. Azamian, who serves as Director, President/CEO, and Board Chair. The filing pertains to transactions that occurred on November 13. The brief notice highlights the company's stock symbol (TARS) and its current performance.

Form 4 Tarsus Pharmaceuticals Inc: Bobak R. Azamian (Director, President/CEO and Board Chair) For: 13 November

https://in.investing.com/news/stock-market-news/form-4-tarsus-pharmaceuticalsinc-bobak-r-azamian-director-presidentceo-and-board-chair-for-13-november-93CH-5711146
This article reports on a Form 4 filing for Tarsus Pharmaceuticals Inc., indicating a transaction by Bobak R. Azamian, who holds positions as Director, President/CEO, and Board Chair. The filing pertains to activity on November 13.

Tarsus (TARS) CEO's trust sells shares at an $80.31 average under an automatic trading plan.

https://www.stocktitan.net/sec-filings/TARS/form-4-tarsus-pharmaceuticals-inc-insider-trading-activity-2c624f6ee641.html
The Bobak Azamian Living Trust, associated with Tarsus Pharmaceuticals' President/CEO and Board Chair Bobak R. Azamian, sold 10,000 common shares of TARS on November 13, 2026, at a weighted average price of $80.31 per share. This transaction was executed automatically under a Rule 10b5-1 trading plan adopted in December 2025. Following the sale, the trust indirectly holds 817,991 shares, and Azamian directly holds an additional 33,421 shares.

A fund's 4.1% holding overlaps a larger reported stake in Tarsus Pharmaceuticals (TARS).

https://www.stocktitan.net/sec-filings/TARS/schedule-13g-a-tarsus-pharmaceuticals-inc-amended-passive-investment--5058300395f2.html
Paradigm BioCapital Advisors LP, its general partner, and Senai Asefaw, M.D., have reported a 4.7% beneficial ownership stake in Tarsus Pharmaceuticals (TARS), totaling 2,301,375 shares. This disclosure, made via an amended SCHEDULE 13G/A filing, notes that Paradigm BioCapital International Fund Ltd., an entity managed by the Adviser, holds 4.1% or 2,028,487 shares, with the larger reported stake overlapping this fund's holding. The percentages are based on 49,303,413 shares of Tarsus common stock outstanding as of September 25, 2026.

Form 144 TARSUS PHARMACEUTICALS INC For: 15 November By Investing.com

https://au.investing.com/news/stock-market-news/form-144-tarsus-pharmaceuticals-inc-for-15-november-93CH-4771822
Investing.com reported on a Form 144 filing by TARSUS PHARMACEUTICALS INC for November 15. The article highlights the company's stock symbol TARS and its performance within the market. This filing provides details on the intent to sell restricted or controlled securities.
Advertisement

Form 144 TARSUS PHARMACEUTICALS INC For: 15 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-tarsus-pharmaceuticals-inc-for-15-november-93CH-5705415
This article from Investing.com announces the filing of Form 144 for TARSUS PHARMACEUTICALS INC, pertaining to activities on November 15. Form 144 indicates an intent to sell restricted or control securities. The brief notice highlights the company's stock symbol TARS and its recent price performance.

Form 4 Tarsus Pharmaceuticals Inc: David E. I. Pyott (Director) For: 15 September

https://ca.investing.com/news/stock-market-news/form-4-tarsus-pharmaceuticalsinc-david-e-i-pyott-director-for-15-september-93CH-4951157
This article announces a Form 4 filing for Tarsus Pharmaceuticals Inc., detailing an insider transaction by Director David E. I. Pyott on September 15. The content is primarily a brief notification of this regulatory filing, indicating an insider trading event. It provides no further details on the nature or value of the transaction.

Tarsus Pharmaceuticals director William Link sells $979,744 in stock

https://www.investing.com/news/insider-trading-news/tarsus-pharmaceuticals-director-william-link-sells-979744-in-stock-93CH-5020229
William J. Link, a director at Tarsus Pharmaceuticals, sold 12,500 shares of the company’s common stock for a total of $979,744 on September 15, 2026, under a pre-arranged trading plan. This sale occurred while Tarsus shares showed strong momentum, with analysts suggesting the stock is undervalued. Separately, Tarsus Pharmaceuticals reported record third-quarter sales of $194.5 million, exceeding forecasts, despite an adjusted loss per share that was higher than expected.

Form 4 Tarsus Pharmaceuticals Inc: Wendy L. Yarno (Director) For: 15 September

https://uk.investing.com/news/stock-market-news/form-4-tarsus-pharmaceuticalsinc-wendy-l-yarno-director-for-15-september-93CH-4975978
This article reports on a Form 4 filing for Tarsus Pharmaceuticals Inc., indicating a transaction involving director Wendy L. Yarno on September 15th. The filing suggests insider activity for the company (TARS). The brief article, published by Investing.com, provides no further details beyond the headline.

Form 4 Tarsus Pharmaceuticals Inc: David E. I. Pyott (Director) For: 15 September

https://uk.investing.com/news/stock-market-news/form-4-tarsus-pharmaceuticalsinc-david-e-i-pyott-director-for-15-september-93CH-4975840
This article reports on a Form 4 filing for Tarsus Pharmaceuticals Inc, detailing insider transaction information for David E. I. Pyott, a director of the company, related to activities on September 15. The brief news item indicates that this information was published on November 11, 2026, at 23:16. The stock symbol TARS is mentioned with a 3.97% gain.
Advertisement

Form 4 Tarsus Pharmaceuticals Inc: William J. Phd Link (Director) For: 15 September

https://ca.investing.com/news/stock-market-news/form-4-tarsus-pharmaceuticalsinc-william-j-phd-link-director-for-15-september-93CH-4951347
This article reports on a Form 4 filing for Tarsus Pharmaceuticals Inc., indicating that William J. Phd Link, a Director, made a transaction on September 15. The publication by Investing.com provides a brief alert regarding this insider trading activity.

Will Wider Q3 Loss Change Tarsus Pharmaceuticals Stock Narrative

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/will-wider-q3-loss-change-tarsus-pharmaceuticals-stock-narra
Tarsus Pharmaceuticals reported a significantly wider net loss of US$668.33 million in Q3 2026 despite higher revenue, driven by heavy spending and acquisition-related charges. This has prompted a re-evaluation of the company's investment narrative, which hinges on the success of XDEMVY and its pipeline programs. Analysts project future profitability by 2029, but the immediate focus is on commercial execution and the ability of increased spending to drive sales volume.

Tarsus Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $101.1, Implies 39% Upside

https://www.tradingview.com/news/tradingview:00be8b2b2a5ea:0-tarsus-pharmaceuticals-inc-stock-12-month-price-target-raised-to-101-1-implies-39-upside/
Tarsus Pharmaceuticals, Inc. (TARS) has seen its average price target raised to $101.1 by 10 analysts, up from $98.89, with individual forecasts ranging from $88 to $116 per share. This updated target suggests a potential upside of approximately 39% from its November 3rd closing price. The consensus rating among 11 covering analysts remains a "Buy," with no "Holds" or "Sells."

More than 5% of Tarsus Pharmaceuticals (TARS) is held in a reported passive stake.

https://www.stocktitan.net/sec-filings/TARS/schedule-13g-tarsus-pharmaceuticals-inc-passive-investment-disclosure-12e2f1167c5c.html
FMR LLC and Abigail P. Johnson have reported a passive stake in Tarsus Pharmaceuticals (TARS), each beneficially owning 3,143,158 shares, which represents 6.4% of the common stock. This disclosure was made via a SCHEDULE 13G SEC filing on November 5, 2026, indicating FMR LLC holds sole voting power over 3,139,690 shares and both FMR LLC and Abigail P. Johnson have sole dispositive power over their respective shares. The filing emphasizes that the stake is held in the ordinary course of business and not for influencing control of the issuer.

Tarsus to Participate in Upcoming Investor Conferences

https://markets.businessinsider.com/news/stocks/tarsus-to-participate-in-upcoming-investor-conferences-1036725537
Tarsus Pharmaceuticals, Inc. announced its management will participate in three upcoming investor conferences: the Guggenheim 3rd Annual Healthcare Conference on November 10th, the 2026 Jefferies Global Healthcare Conference on November 18th and 19th, and the Piper Sandler 38th Annual Healthcare Conference on December 1st. Live webcasts and replays for fireside chats will be available on the Tarsus website. The company is focused on developing treatments for various diseases, including the FDA-approved XDEMVY for Demodex blepharitis.
Advertisement

Tarsus Pharmaceuticals Inc (TARS) (Q3 2026) Earnings Call Highlights: Record Xtendi Sales and ...

https://sg.finance.yahoo.com/news/tarsus-pharmaceuticals-inc-tars-q3-030455767.html
Tarsus Pharmaceuticals reported record Q3 2026 Xtendi net product sales of $194.6 million, a 64% year-over-year increase, and raised its full-year guidance to $715-$730 million. The company highlighted strong patient demand, increased eye care professional adoption, and a robust pipeline with five potential new medicines, despite elevated SG&A expenses and significant acquired IPR&D charges. Management addressed concerns about future Xtendi growth, DTC spend, and pipeline development for Stargardt disease and ocular rosacea.

Tarsus Pharmaceuticals, Inc. (TARS) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/TARS/
This article provides a comprehensive overview of Tarsus Pharmaceuticals, Inc. (TARS), including its latest stock price, financial data, and company profile. It details the company's focus on developing therapeutic candidates for eye care, such as XDEMVY for demodex blepharitis, and its pipeline projects for ocular rosacea and Lyme disease prevention. The report also includes analyst insights, earnings trends, and performance comparisons against the S&P 500.

Tarsus Pharmaceuticals Revenue Climbs 63.9% to $194.5 Million in Q3

https://www.tokenpost.com/news/business/48313
Tarsus Pharmaceuticals reported a significant increase in its third-quarter revenue, reaching $194.5 million, which represents a 63.9% year-over-year climb. Despite this revenue growth, the company recorded a GAAP earnings per share of -$14.40. As of September 30, Tarsus Pharmaceuticals held $309.6 million in cash, cash equivalents, and marketable securities.

Tarsus Pharmaceuticals Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62848818/tarsus-pharmaceuticals-q3-2026-earnings-call-transcript
Tarsus Pharmaceuticals reported record Q3 2026 net sales of $194.6 million for XDEMVY, driven by strong prescription volumes and increased demand. The company raised its full-year 2026 sales outlook for XDEMVY to $715-$730 million and is advancing its pipeline with five potential new medicines, including programs for ocular rosacea and Lyme disease prevention. Management emphasized the success of DTC investments, particularly a John Cena campaign, and the integration of two recent acquisitions, Irenix and Alkias.

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

https://finance.yahoo.com/healthcare/articles/tarsus-pharmaceuticals-inc-tars-reports-235509435.html
Tarsus Pharmaceuticals, Inc. (TARS) reported a Q3 loss of $0.78 per share, outperforming the Zacks Consensus Estimate of a $1.43 loss, and posted revenues of $194.57 million, surpassing estimates by 3.06%. Despite these positive surprises, the company's shares have declined by 10.5% year-to-date, contrasting with the S&P 500's gain. The stock currently holds a Zacks Rank #2 (Buy), indicating an expectation to outperform the market in the near future.
Advertisement

Tarsus Pharmaceuticals, Inc. (TARS) Misses Q3 EPS by 1293c

https://www.streetinsider.com/Earnings/Tarsus+Pharmaceuticals%2C+Inc.+%28TARS%29+Misses+Q3+EPS+by+1293c/27283455.html
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported a significant miss in its Q3 EPS, coming in at ($14.40) against an analyst estimate of ($1.47), a difference of $12.93. Despite the earnings miss, the company's revenue for the quarter exceeded expectations, reaching $194.5 million compared to the consensus estimate of $183.95 million.

Tarsus Reports Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/11/03/3394778/0/en/tarsus-reports-third-quarter-2026-financial-results.html
Tarsus Pharmaceuticals, Inc. announced strong financial results for Q3 2026, driven by record XDEMVY net product sales of $194.6 million, a 64% year-over-year increase. The company surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales since launch, while also progressing its pipeline and appointing Neera Clase as Chief Commercial Officer.

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

https://ca.finance.yahoo.com/news/tarsus-pharmaceuticals-inc-tars-reports-235509435.html
Tarsus Pharmaceuticals, Inc. (TARS) reported a Q3 loss of $0.78 per share, outperforming the Zacks Consensus Estimate of a $1.43 loss, and posted revenues of $194.57 million, exceeding estimates by 3.06%. The company has surpassed revenue estimates four times in the last four quarters. Despite underperforming the S&P 500 year-to-date, the stock currently holds a Zacks Rank #2 (Buy), indicating expected market outperformance in the near future.

Learn Why The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following CCO Appointment

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/learn-why-the-bull-case-for-tarsus-pharmaceuticals-tars-coul
Tarsus Pharmaceuticals has appointed Neera Clase as Chief Commercial Officer, effective November 1, 2026, consolidating commercial execution for XDEMVY and other eye care programs under her leadership. This move is significant as the company approaches its Q3 2026 earnings report, where investors will closely monitor XDEMVY's market penetration and associated spending. Analysts project substantial revenue and earnings growth for Tarsus by 2029, with some anticipating even higher figures based on successful pipeline execution.

Tarsus Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $98.89, Implies 37% Upside

https://www.tradingview.com/news/tradingview:6742613476b90:0-tarsus-pharmaceuticals-inc-stock-12-month-price-target-cut-to-98-89-implies-37-upside/
Tarsus Pharmaceuticals, Inc. (TARS) has seen its average 12-month price target adjusted down slightly by analysts from $99.4 to $98.89, with individual forecasts ranging from $84 to $116 per share. This updated target suggests a potential upside of approximately 37% from its Oct. 28 closing price. The consensus among 11 analysts remains a "Buy" rating.
Advertisement

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

https://www.globenewswire.com/news-release/2026/10/29/3391879/0/en/tarsus-to-report-third-quarter-2026-financial-results-on-tuesday-november-3-2026.html
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced it will host a live webcast on Tuesday, November 3, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third-quarter 2026 financial results and provide a corporate update. A recorded version of the webcast will be available on their website for approximately 90 days. The company is advancing its pipeline in eye care, dermatology, and infectious disease prevention, including FDA-approved XDEMVY® for Demodex blepharitis.

Tarsus Pharmaceuticals Names Neera Clase Chief Commercial Officer

https://www.visionmonday.com/people/moves/article/tarsus-pharmaceuticals-names-neera-clase-chief-commercial-officer/
Tarsus Pharmaceuticals Inc. has appointed Neera Clase as its new chief commercial officer, effective November 1, 2026. Clase, who previously served as interim CCO and senior vice president of market access, will lead commercial strategy, focusing on expanding Xdemvy's reach and advancing the company's pipeline, which includes retina programs and treatments for ocular rosacea and Lyme disease. CEO Bobby Azamian praised her instrumental role in Xdemvy's market success, anticipating her leadership will drive future growth.

Tarsus Pharmaceuticals names Neera Clase as chief commercial officer

https://www.streetinsider.com/Management+Changes/Tarsus+Pharmaceuticals+names+Neera+Clase+as+chief+commercial+officer/27245384.html
Tarsus Pharmaceuticals has appointed Neera Clase as Chief Commercial Officer, effective November 1, 2026. Clase, who previously served as Interim Chief Commercial Officer and Senior Vice President of Market Access, will oversee the commercial strategy for the company's FDA-approved treatment, XDEMVY, and its pipeline. She aims to expand XDEMVY's reach, believing it has the potential to exceed $2 billion in peak sales.

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

https://www.stocktitan.net/news/TARS/tarsus-pharmaceuticals-appoints-neera-clase-as-chief-commercial-nqok7pqnsyta.html
Tarsus Pharmaceuticals has appointed Neera Clase as Chief Commercial Officer, effective November 1, 2026. Clase, who previously served as Interim CCO and SVP of Market Access, will lead commercial strategy, focusing on expanding XDEMVY’s reach and overseeing commercial planning for four investigational programs. She believes XDEMVY has the potential to exceed $2 billion in peak sales.

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

https://www.globenewswire.com/news-release/2026/10/28/3390159/0/en/tarsus-pharmaceuticals-appoints-neera-clase-as-chief-commercial-officer.html
Tarsus Pharmaceuticals has appointed Neera Clase as its new Chief Commercial Officer, effective November 1, 2026. Ms. Clase, who previously served as Interim CCO and SVP of Market Access, will lead the company's commercial strategy, focusing on expanding the reach of XDEMVY and advancing its pipeline in eye care. Her appointment is expected to drive growth and bring future innovations to more patients.
Advertisement

Tarsus Pharmaceuticals Stock In Focus After Large Share Shelf Filings

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/tarsus-pharmaceuticals-stock-in-focus-after-large-share-shel/amp
Tarsus Pharmaceuticals recently filed two shelf registrations in October 2026, totaling US$382.5 million, which grants the company significant flexibility to raise equity capital. This move primarily impacts how Tarsus may fund its XDEMVY commercialization and pipeline work, rather than addressing the core commercial or clinical uncertainties. The filings also provide levers for continued growth spending, with analysts projecting substantial revenue and earnings expansion by 2029.

Tarsus Pharmaceuticals, Inc. Estimates – NASDAQ:TARS

https://www.tradingview.com/symbols/NASDAQ-TARS/financials-estimates/
This article provides an overview of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) financial data and analyst estimates on TradingView. It offers access to reported financial data and analyst projections across income statements, balance sheets, cash flow statements, and valuation metrics, allowing users to compare actual results with estimates and visualize trends. The platform includes disclaimers that the information is not investment advice.

Tarsus Pharmaceuticals (TARS) Institutional Ownership 2026 $TARS

https://www.marketbeat.com/stocks/NASDAQ/TARS/institutional-ownership/
This article details the institutional ownership of Tarsus Pharmaceuticals (TARS), providing a comprehensive list of major shareholders and their recent transactions. It indicates that institutional investors own 90.01% of the stock, with significant buying and selling activity over the past 24 months. The report identifies top institutional buyers and sellers, along with their respective transaction volumes.

Tarsus Pharmaceuticals (TARS) Could Be 32% Undervalued After New Shelf Registrations

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/tarsus-pharmaceuticals-tars-could-be-32-undervalued-after-ne/amp
Tarsus Pharmaceuticals (TARS) recently filed two shelf registrations totaling US$382 million, a move that comes amidst a short-term stock price decline. Despite recent dips, the company is considered 32% undervalued with a fair value of $99.50 per share, driven by pipeline expansion and future earnings potential, though risks like XDEMVY uptake and high spending could impact profitability.

Tarsus Pharmaceuticals (TARS) Could Be 32% Undervalued After New Shelf Registrations

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/tarsus-pharmaceuticals-tars-could-be-32-undervalued-after-ne
Tarsus Pharmaceuticals (TARS) recently filed two shelf registrations for potential share offerings totaling US$382 million, a move that could signal future fundraising. Despite a recent 12% drop in share price over the past month, the company is still considered 32% undervalued with a fair value estimated at $99.50 per share, compared to its last close of $68.07. This valuation is supported by pipeline expansion and expected long-term earnings growth, although risks remain if product uptake disappoints or profitability is pressured by high spending.
Advertisement

Liquidity Mapping Around (TARS) Price Events

https://news.stocktradersdaily.com/news_release/149/Liquidity_Mapping_Around_TARS_Price_Events_101426104802_1791989282.html
This article analyzes Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) with a focus on liquidity mapping and AI-generated trading strategies. It identifies weak near and mid-term sentiment, a neutral long-term outlook, and an exceptional risk-reward setup targeting a 16.5% gain. The piece outlines specific trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, based on multi-timeframe signal analysis.

Form S-3ASR Tarsus Pharmaceuticals Inc For: 13 October By Investing.com

https://in.investing.com/news/stock-market-news/form-s3asr-tarsus-pharmaceuticalsinc-for-13-october-93CH-5631811
This article announces that Tarsus Pharmaceuticals Inc filed a Form S-3ASR on October 13. The filing is a standard SEC form used by eligible companies for efficient securities registration. The article provides no further details beyond the filing date and company name.

Form S-3ASR Tarsus Pharmaceuticals Inc For: 13 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-s3asr-tarsus-pharmaceuticalsinc-for-13-october-93CH-2735010
This article reports that Tarsus Pharmaceuticals Inc. filed a Form S-3ASR on October 13. The brief notice from Investing.com indicates this financial filing and includes the company's stock symbol TARS. The content primarily focuses on market data and other news.

Analysts Are Bullish on These Healthcare Stocks: Merck & Company (MRK), Tarsus Pharmaceuticals (TARS)

https://www.theglobeandmail.com/investing/markets/stocks/MRK/pressreleases/6635038/analysts-are-bullish-on-these-healthcare-stocks-merck-company-mrk-tarsus-pharmaceuticals-tars/
Analysts from Barclays and J.P. Morgan have issued bullish sentiments on several healthcare stocks, including Merck & Company (MRK), Tarsus Pharmaceuticals (TARS), and Ascendis Pharma (ASND). Merck & Company received a Buy rating with a $150 price target from Barclays, while Tarsus Pharmaceuticals also secured a Buy rating and a $110 price target from Barclays. Ascendis Pharma was reiterated with a Buy rating by J.P. Morgan, indicating strong analyst confidence across these pharmaceutical companies.

Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $110

https://www.moomoo.com/news/post/1000935775/barclays-maintains-tarsus-pharmaceuticals-tarsus-with-buy-rating-maintains-target
Barclays has reiterated its Buy rating for Tarsus Pharmaceuticals (TARS.US) and maintained a target price of $110. This indicates the firm's continued positive outlook on the company's stock performance.
Advertisement

Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Profit Outlook

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/tarsus-pharmaceuticals-incs-nasdaqtars-profit-outlook
Tarsus Pharmaceuticals (NASDAQ:TARS) is nearing profitability, with analysts predicting a breakeven in 2027 after a US$46m trailing-twelve-month loss. The company is expected to achieve positive profits of US$6.9m in 2027, driven by an optimistic 64% year-on-year growth rate. Tarsus Pharmaceuticals is funding operations predominantly from equity capital, maintaining a low debt-to-equity ratio of 21%, which reduces investment risk.

Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100

https://www.moomoo.com/news/post/1000554704/oppenheimer-maintains-tarsus-pharmaceuticals-tarsus-with-buy-rating-maintains-target
Oppenheimer has reiterated its Buy rating for Tarsus Pharmaceuticals (TARS.US), maintaining a price target of $100. This indicates the firm's continued confidence in the company's financial prospects and stock performance.

Tarsus Pharmaceuticals, Inc. (TARS) stock price, news, quote and history

https://au.finance.yahoo.com/quote/TARS/
Tarsus Pharmaceuticals, Inc. (TARS) experienced a slight decline of 4.01% in its stock price, closing at $75.46. The company, a commercial-stage biopharmaceutical firm, focuses on eye care therapeutics, including its product XDEMVY for demodex blepharitis, and has other candidates in development for ocular rosacea and Lyme disease. Analysts maintain a "Buy" rating with an average target price of $99.50.

Tarsus Pharmaceuticals, Inc. (TARS) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/TARS/
Tarsus Pharmaceuticals, Inc. (TARS) stock closed at $75.46, down 4.01% on October 1st, 2026, with after-hours trading showing a slight increase. The company focuses on developing therapeutic candidates for eye care, including XDEMVY for Demodex blepharitis, and has several other candidates in clinical trials. Tarsus has shown strong 1-year, 3-year, and 5-year returns, outperforming the S&P 500.

Tiny mites cause over two-thirds of blepharitis cases, an eyelid disease. Tarsus plans 11 presentations.

https://www.stocktitan.net/news/TARS/tarsus-plans-to-present-11-abstracts-highlighting-new-insights-in-poxu07l2n5jx.html
Tarsus Pharmaceuticals (TARS) is set to present 11 scientific abstracts at the American Academy of Optometry 2026 Annual Meeting. These presentations will offer new insights into Demodex blepharitis, ocular rosacea, and real-world outcomes with their product XDEMVY. The company highlights the significant impact of Demodex mites, which cause over two-thirds of blepharitis cases, and the high prevalence of ocular rosacea.
Advertisement

Pyott David E I Executes Options in Tarsus Pharmaceuticals, Retains 9,575 Shares

https://kalkinemedia.com/us/news/announcements/pyott-david-e-i-executes-options-in-tarsus-pharmaceuticals-retains-9575-shares
Pyott David E I, a director of Tarsus Pharmaceuticals (NASDAQ: TARS), recently exercised options resulting in a holding of 9,575 shares, which represents approximately 2.1% of his total shares in the company. This transaction also accounted for about 24.9% of his previous derivative securities holdings. The option exercise took place on September 15, 2026.

Tarsus Pharmaceuticals (TARS) director adds 201 shares through RSU conversion

https://www.stocktitan.net/sec-filings/TARS/form-4-tarsus-pharmaceuticals-inc-insider-trading-activity-75d0bb6754a5.html
Tarsus Pharmaceuticals director David E. I. Pyott converted 201 Restricted Stock Units (RSUs) into common shares on September 15, 2026, which are now held indirectly through his trust. Following this transaction, his trust holds 9,575 common shares, and he retains 605 RSUs that will vest in equal installments through June 2027. This transaction, reported via a Form 4 SEC filing, indicates a neutral impact and sentiment.

Tarsus Pharmaceuticals (TARS) director sells shares under preset plan

https://www.stocktitan.net/sec-filings/TARS/form-4-tarsus-pharmaceuticals-inc-insider-trading-activity-c5da2c46bc90.html
Tarsus Pharmaceuticals director William J. Link sold 12,500 common shares at weighted average prices around $79 under a pre-planned Rule 10b5-1 trading plan. This transaction followed the exercise of 201 Restricted Stock Units (RSUs) into common stock on September 15, 2026. After these sales, Link holds 94,487 common shares and 605 RSUs.

Nearly $1M Tarsus (NASDAQ: TARS) insider share sale planned by a company director

https://www.stocktitan.net/sec-filings/TARS/144-tarsus-pharmaceuticals-inc-sec-filing-ec102c7216f4.html
Tarsus Pharmaceuticals, Inc. (TARS) director J. Link plans to sell 12,500 shares of common stock, valued at approximately $979,745.36, through Merrill Lynch on or about September 15, 2026. These shares were acquired via a stock option exercise in January 2017. This transaction was disclosed in a Rule 144 notice, which outlines conditions for reselling restricted or insider-held shares to the public.

Tarsus Pharmaceuticals Finalizes Acquisition of Alkeus Pharmaceuticals with $270M Cash and Stock Deal

https://kalkinemedia.com/us/news/announcements/tarsus-pharmaceuticals-finalizes-acquisition-of-alkeus-pharmaceuticals-with-270m-cash-and-stock-deal
Tarsus Pharmaceuticals has completed its acquisition of Alkeus Pharmaceuticals for an initial payment of $270 million in cash and 2,908,692 shares of Tarsus common stock. The deal also includes potential milestone payments of up to $350 million tied to regulatory approval and the first U.S. sale of an Alkeus product, along with tiered revenue sharing. Alkeus will continue to operate as a wholly-owned subsidiary of Tarsus.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement